Publications

Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.

MLL frequently hosts international research cooperation directly: For
instance through exchange programs, our test procedures and data
repositories, but also by allowing guest researchers to shadow the work
of our facility and by sitting on national and international work
groups.

We also support research institutions around the world to
produce new insight in the field of leukemia diagnostics and emergence,
as well as in the rollout of new procedures and applications for routine
diagnostics in the facilities themselves.

Overview of our publications

Proximally biased V(D)J recombination in the clonal evolution of IGH alleles in KMT2A::AFF1 BCP‐ALL of all age classes

Müller H, Dicker F, Bär C, Walter W, Hutter S, Nadarajah N, Meggendorfer M, Gao Q, Iacobucci I, Mullighan CG, Kern W, Haferlach T, Haferlach C. Proximally biased V(D)J recombination in the clonal evolution of IGH alleles in KMT2A::AFF1 BCP‐ALL of all age classes. Hemasphere. 2024.

Read more

Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.

Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C, Müller M, Dahlhoff M, Boersma A, Rülicke T, Fleck R, de Araujo ED, Gunning PT, Aittokallio T, Mustjoki S, Sanda T, Hartmann S, Grebien F, Hoermann G, Haferlach T, Staber PB, Neubauer HA, Look AT, Herling M, Moriggl R. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia. The Journal of Clinical Investigation. 2024.

Read more

Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis.

Piehler AP, Truger M, Kozik JH, Weissmann S, Schwonzen M, Meggendorfer M, Kern W, Haferlach T, Hoermann G, Haferlach C. Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis. Haematologica. 2024.

Read more

Recommendations for using artificial intelligence in clinical flow cytometry

Ng DP, Simonson PD, Tarnok A, Lucas F, Kern W, Rolf N, Bogdanoski G, Green C, Brinkman RR, Czechowska K. Recommendations for using artificial intelligence in clinical flow cytometry. Cytometry B Clin Cytom. 2024.

Read more

Translating the regulatory landscape of medical devices to create fit-for-purpose artificial intelligence (AI) cytometry solutions

Bogdanoski G, Lucas F, Kern W, Czechowska K. Translating the regulatory landscape of medical devices to create fit-for-purpose artificial intelligence (AI) cytometry solutions. Cytometry B Clin Cytom. 2024.

Read more

Precise single-cell transcriptomic mapping of normal and leukemic cell states reveals unconventional lineage priming in acute myeloid leukemia

Zeng AGX, Iacobucci I, Shah S, Mitchell A, Wong G, Bansal S, Gao Q, Kim H, Kennedy JA, Minden MD, Haferlach T, Mullighan CG, Dick JE.. Precise single-cell transcriptomic mapping of normal and leukemic cell states reveals unconventional lineage priming in acute myeloid leukemia. bioRxiv. 2023.

Read more

Prognostic impact of CEBPA mutational subgroups in adult AML

Georgi JA, Stasik S, Kramer M, Meggendorfer M, Röllig C, Haferlach T, Valk P, Linch D, Herold T, Duployez N, Taube F, Middeke JM, Platzbecker U, Serve H, Baldus CD, Muller-Tidow C, Haferlach C, Koch S, Berdel WE, Woermann BJ, Krug U, Braess J, Hiddemann W, Spiekermann K, Boertjes EL, Hills RK, Burnett A, Ehninger G, Metzeler K, Rothenberg-Thurley M, Dufour A, Dombret H, Pautas C, Preudhomme C, Fenwarth L, Bornhäuser M, Gale R, Thiede C.. Prognostic impact of CEBPA mutational subgroups in adult AML. Leukemia. 2024.

Read more

You may also be interested in

Diagnostics

Our goal is to provide the best leukemia diagnostics for our patients through a comprehensive set of methods, state-of-the-art equipment and continuous development.

Learn more

Services

Do you have questions about sample submission, analyses performed or findings? Here you will find contact details, contact persons and our most frequently asked questions (FAQs).

Learn more

About us

We believe that exceptional things happen when knowledge, courage and responsibility come together. In a world that offers so many possibilities, our goal is to make the best possible leukemia diagnostics available worldwide and to all patients.

Learn more